These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 38835773)

  • 21. Current gaps in sepsis immunology: new opportunities for translational research.
    Rubio I; Osuchowski MF; Shankar-Hari M; Skirecki T; Winkler MS; Lachmann G; La Rosée P; Monneret G; Venet F; Bauer M; Brunkhorst FM; Kox M; Cavaillon JM; Uhle F; Weigand MA; Flohé SB; Wiersinga WJ; Martin-Fernandez M; Almansa R; Martin-Loeches I; Torres A; Giamarellos-Bourboulis EJ; Girardis M; Cossarizza A; Netea MG; van der Poll T; Scherag A; Meisel C; Schefold JC; Bermejo-Martín JF
    Lancet Infect Dis; 2019 Dec; 19(12):e422-e436. PubMed ID: 31630991
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New approaches to the study of sepsis.
    Ward PA
    EMBO Mol Med; 2012 Dec; 4(12):1234-43. PubMed ID: 23208733
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Surgical sepsis: dysregulation of immune function and therapeutic implications.
    Boontham P; Chandran P; Rowlands B; Eremin O
    Surgeon; 2003 Aug; 1(4):187-206. PubMed ID: 15570763
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Host response to Candida albicans bloodstream infection and sepsis.
    Duggan S; Leonhardt I; Hünniger K; Kurzai O
    Virulence; 2015; 6(4):316-26. PubMed ID: 25785541
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunostimulation is a rational therapeutic strategy in sepsis.
    Pugin J
    Novartis Found Symp; 2007; 280():21-7; discussion 27-36, 160-4. PubMed ID: 17380786
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting Toll-Like Receptors in Sepsis: From Bench to Clinical Trials.
    Chen F; Zou L; Williams B; Chao W
    Antioxid Redox Signal; 2021 Nov; 35(15):1324-1339. PubMed ID: 33588628
    [No Abstract]   [Full Text] [Related]  

  • 27. Targeting macrophage immunometabolism: Dawn in the darkness of sepsis.
    Kumar V
    Int Immunopharmacol; 2018 May; 58():173-185. PubMed ID: 29625385
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Study progress of role of co-suppressor molecules in sepsis immune dysfunction].
    Gao J; Liu Z; Liu Z
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2020 Jan; 32(1):121-125. PubMed ID: 32148245
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunosuppression in sepsis.
    Lyn-Kew K; Standiford TJ
    Curr Pharm Des; 2008; 14(19):1870-81. PubMed ID: 18691098
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Regulatory T cell populations in sepsis and trauma.
    Venet F; Chung CS; Monneret G; Huang X; Horner B; Garber M; Ayala A
    J Leukoc Biol; 2008 Mar; 83(3):523-35. PubMed ID: 17913974
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Personalised immunotherapy in sepsis: a scoping review protocol.
    Slim MA; van Mourik N; Dionne JC; Oczkowski SJW; Netea MG; Pickkers P; Giamarellos-Bourboulis EJ; Müller MCA; van der Poll T; Wiersinga WJ; Vlaar APJ; van Vught LA
    BMJ Open; 2022 May; 12(5):e060411. PubMed ID: 35534059
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modulation of innate immune responses in the treatment of sepsis and pneumonia.
    Schultz MJ; van der Poll T
    Curr Drug Targets Inflamm Allergy; 2004 Mar; 3(1):11-7. PubMed ID: 15032638
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunomodulatory therapies in sepsis.
    Kox WJ; Volk T; Kox SN; Volk HD
    Intensive Care Med; 2000; 26 Suppl 1():S124-8. PubMed ID: 10786969
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Using innate immunity to characterize the host response to microbial invasion in severe sepsis.
    Warner EA; Moldawer LL
    Future Microbiol; 2008 Apr; 3(2):177-89. PubMed ID: 18366338
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting cytokines as a treatment for patients with sepsis: A lost cause or a strategy still worthy of pursuit?
    Brown KA; Brown GA; Lewis SM; Beale R; Treacher DF
    Int Immunopharmacol; 2016 Jul; 36():291-299. PubMed ID: 27208433
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mathematical Model of Innate and Adaptive Immunity of Sepsis: A Modeling and Simulation Study of Infectious Disease.
    Shi Z; Wu CH; Ben-Arieh D; Simpson SQ
    Biomed Res Int; 2015; 2015():504259. PubMed ID: 26446682
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sepsis-induced immune dysfunction: can immune therapies reduce mortality?
    Delano MJ; Ward PA
    J Clin Invest; 2016 Jan; 126(1):23-31. PubMed ID: 26727230
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunometabolism: Another Road to Sepsis and Its Therapeutic Targeting.
    Kumar V
    Inflammation; 2019 Jun; 42(3):765-788. PubMed ID: 30506105
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of ethanol exposure on innate immune response in sepsis.
    Roychowdhury S; Pant B; Cross E; Scheraga R; Vachharajani V
    J Leukoc Biol; 2024 May; 115(6):1029-1041. PubMed ID: 38066660
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of cellular events in the pathophysiology of sepsis.
    Bhan C; Dipankar P; Chakraborty P; Sarangi PP
    Inflamm Res; 2016 Nov; 65(11):853-868. PubMed ID: 27392441
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.